



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Camcevi

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0006/G	This was an application for a group of variations. B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.IV.1.z - Change of a measuring or administration	05/07/2024		SmPC, Labelling and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	device - Other variation				
IB/0007	B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation	21/06/2024	n/a		
N/0008	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	19/06/2024		PL	
PSUSA/10877 /202307	Periodic Safety Update EU Single assessment - leuprorelin (depot formulations)	21/03/2024	27/05/2024	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10877/202307.
IB/0004/G	This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor	22/05/2024	n/a		

	changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.d.1.b.1 - Stability of AS - Change in the storage conditions - Change to more restrictive storage conditions of the AS B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer				
IA/0005/G	This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	27/02/2024	n/a		

	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IA/0003/G	This was an application for a group of variations. B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new	23/02/2024	n/a		

	specification parameter to the specification with its corresponding test method				
IB/0001	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	11/05/2023	27/05/2024	SmPC and PL	